Rochester BioVenture Center November 14th



Similar documents
Basic Overview of Preclinical Toxicology Animal Models

Biological importance of metabolites. Safety and efficacy aspects

exactly. The need for efficiency in developing effective new therapeutics has never been greater.

Guidance for Industry Safety Testing of Drug Metabolites

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

Non-clinical development of biologics

Session 6 Clinical Trial Assessment Phase I Clinical Trial

Recommended Dose Volumes for Common Laboratory Animals IQ 3Rs Leadership Group - Contract Research Organization Working Group

Guidance for Industry

4.1 Objectives of Clinical Trial Assessment

Lead optimization services

Alterações empresariais sustentadas pelo conceito de engenharia do Produto Patrício Soares da Silva, MD, PhD

BIOTECHNOLOGY OPERATIONS

DMPK: Experimentation & Data

ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals

Overview of Drug Development: the Regulatory Process

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

Adjuvants and Excipients

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013

DZIF-Product Development Unit (PDU)

FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN

Product Development Services for Global Registration of Drugs & Biologics th April Contact: kevin.breesch@toxikon.be

Guidance for Industry

Pharmacology skills for drug discovery. Why is pharmacology important?

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE M3(R2)

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials

SAFETY PHARMACOLOGY STUDIES FOR HUMAN PHARMACEUTICALS S7A

Guidance for Industry

A FDA Perspective on Nanomedicine Current Initiatives in the US

General toxicity study designs

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

Course Curriculum for Master Degree in Clinical Pharmacy

Guidance for Industry

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting -

Oncology Drug Development

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group

Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer

How to develop Antibody Drug Conjugates: Bioanalysis Contribution

Risk Assessment of Pesticides Residue by JMPR - To set ADI and ARfD-

News in Nonclinical Evaluation of Anticancer Pharmaceuticals: ICH guideline S9 and beyond

Goals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe

Challenges in the Regulation of Pediatric Clinical Trials

POLICY AND PROCEDURES OFFICE OF NEW DRUGS. Good Review Practice: Management of Breakthrough Therapy-Designated Drugs and Biologics.

Corporate Presentation November, 2013

Risk Assessment in Chemical Food Safety. Dept. of Food Safety and Zoonoses (FOS)

CTC Technology Readiness Levels

SERVICES FOR. Devices and Combination Products

Medicines for Neglected Diseases Workshop. Dennis Liotta, Ph.D. Director Emory Institute for Drug Discovery Atlanta, Georgia

Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies

Chemical safety and big data: the industry s demands

Importing pharmaceutical products to China

Call 2014: High throughput screening of therapeutic molecules and rare diseases

Human ADME and Studies with Radiolabeled Compounds: Phase I-IIa

dixa a data infrastructure for chemical safety Jos Kleinjans Dept of Toxicogenomics Maastricht University

TERM SHEET EXAMPLE. 1 P age

Testing Services for Large Molecule Drug Development

CTD Dossier Preparation. Sr.Manager-Regulatory Affairs

The Aptuit Center for Drug Discovery & Development Verona, Italy. Uncommon Expertise. Exceptional Results.

Apply with Resume to: Submenu Path Company/Careers/Current Openings/Job Type: Science

PPD LABORATORIES CENTRAL LAB: SUPERIOR SERVICE, QUALITY DATA WITHOUT COMPROMISES

The Clinical Trials Process an educated patient s guide

TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben?

ASMS Regulated Bioanalysis Interest Group (RBIG) Workshop. Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis.

General Principles for the Safety Assessment of Excipients

Medical Therapies Limited EGM Presentation

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S7B

CCAC Animal Data Report

The Impact of Drug-Related QT Prolongation on FDA Regulatory Decisions

Guidance on dose level selection for regulatory general toxicology studies for pharmaceuticals

Presented at: Jefferies 2015 Global Healthcare Conference

Current version dated 5 March 2012

FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE

Roles & Responsibilities of the Sponsor

Valentina Gualato, Ph.D. Process Development Scientist

Animals and medicines research Animal research for the discovery and development of new medicines

September 19, 1984 FOOD PRODUCTION AND DIRECTION GÉNÉRALE, SECTION INSPECTION BRANCH PRODUCTION ET INSPECTION PESTICIDES DES ALIMENTS TRADE MEMORANDUM

Delivering gene therapy to patients

How To Use An Antibody

Quality by Design Concept

BioBusiness Biopharmaceutical Ingredients Recombinant albumins & albumin fusion Dermot Pearson, Strategic Product Director, NZ Biopharma

Chemical Name: Acetone CAS: Synonyms: propanone, β-ketopropane, dimethyl ketone, dimethylformaldehyde, DMK, 2-propanone, propan-2-one

ISO Biological Evaluation of Medical Devices

From Drug Discovery to First in Humans

THE BIOTECH & PHARMACEUTICAL INDUSTRY

Outsourcing in Drug Development From the Bench to the Market. Steven A. Kates, PhD Ischemix LLC

PEOPLE > SCIENCE > SOLUTIONS

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

Introduction to Enteris BioPharma

Drug Development Process

US Regulations for Import and Export of Cell Therapy Products

Transcription:

Rochester BioVenture Center November 14th

Calvert Holdings, Inc. Established in 1996 Parent company for several subsidiaries Focus: health care services and investments Corporate HQ located in Cary, NC 2

Calvert Holdings Companies Calvert Labs (Scranton, PA) Preclinical CRO Acquired in 2000 by Calvert Holdings Calvert Creative (Cary, NC) Marketing agency Identity design & rebranding Website design and rebranding 3

Executive Management Team R. C. McLauchlan Chairman & Chief Executive Officer Charles B. Spainhour, V.M.D, Ph.D., D.A.B.T President & Chief Scientific Officer, Calvert Labs, Chief Scientific Officer, Calvert Holdings David Morgan Executive VP and Chief Operating Officer Michael Recny, Ph.D. Executive VP Investment Strategies Andy Burch Vice President, Business Development 4

Calvert Labs History Founded in 1969 by Dr. Richard Matthews (Pharmakon) Developed out of one of the first CROs in the pharma industry First CRO to offer services in pharmacology 40 years of experience operating in FDA regulated industry Comprehensive record of submissions globally (FDA, Health Canada, MHLW & PMDA (Japan), EU, EPA, SFDA (China)) 5

Calvert Labs Overview Fully GLP compliant 150+ collective years of experience No study ever rejected for reasons of design or technical performance FDA inspections occurred in 2004, 2006, 2009 and 2010; no 483s issued Averages 18 to 24 full IND-enabling programs and 8 to 12 BLA programs completed each year Serve on average 400 hundred clients each year researching technologies in a variety of therapeutic areas. 6

Scientific Services Discovery services Efficacy testing, autoimmune / inflammation assays and models, anti-cancer models, anti-infective models, immunomodulation Pharmacology Discovery pharmacology, Safety pharmacology, Toxicology Acute tox, subchronic / chronic, carcinogenicity, reproductive/ developmental, immunotoxicology PK / ADME Pharmacokinetics / toxicokinetics, screening services Telemetry, pathology, bioanalytical services 7

Support Services Regulatory guidance Clinical pathology Hematology, coagulation, clinical chemistry, urinalysis Lab animal medicine AALAC, AALAS, IACUC Pathology/histology Archiving services SBIR grant support Potential service-for-equity partnerships 8

Our Clients Small to mid-size biotech/pharma Big pharma Medical Device companies Chemical companies Personal care companies Academic R&D ~ 85% of our business is repeat business 9

The Calvert Difference Customized Tailored individual study designs Adjust quickly to changing needs Responsive Ongoing personal communication with your study director Streamlined data collection and entry with Xybion (Pristima TM software) Proven 150+ collective years of experience in design and submission of INDenabling studies No study ever rejected for reasons of design or technical performance 10

Client Testimonial Thanks to a strong IND filed with the FDA, we are now initiating our first-in-man studies for our current lead drug candidate. Our internal team with the help of excellent work conducted by our partners like Calvert, the Agency cleared our IND package with no questions or concerns raised. Calvertʼs team was also critical to completing several key IND enabling studies for a lead compound at my previous company. It is always great to work with this partner on key non-clinical studies. - President and Chief Scientific Officer, Altheos, Inc. 11

Thank you! 12

Appendix 13

Preclinical Capabilities Toxicology Acute, subchronic, chronic Carcinogenicity Developmental Reproductive Multi-generation Pharmacokinetics/toxicokin etics and ADME Telemetry Dog and primate Immunology/immunotoxicol ogy Safety pharmacology Discovery pharmacology General pharmacology Bioanalytical analysis 14

Areas of Expertise Vaccine safety testing Gene therapy safety assessment Human and vet product safety evaluation Biologics safety testing Ocular studies Wound healing studies Dermal studies Customized rodent surgical models for novel drug development Novel studies; client-tailored studies Infusion Development of novel routes Telemetry (canine & primate) Immunoassays (design, validation and analysis) Screening programs Cardiovascular pharmacology In vivo QT prolongation studies bioassay Radioisotopic work Contract archiving services Bioanalytical support 15

Toxicology Services Regulatory (FDA, EPA, EU, ICH, MHW, OECD) Acute toxicology Subchronic/chronic toxicology Carcinogenicity Local hamster tolerance Reproductive/developmental toxicology Dermal toxicology Immunotoxicology 16

Pharmacokinetics/Toxicokinetics Preclinical pharmacokinetics from study design to report Toxicokinetics study and prediction of human exposure Flexible and customized reports C max, T max, AUC, AUMC, K e, T 1/2, e, MRT, Cls, Vdss, Cl/F, Vd/F, F 17

In Vivo and In Vitro ADME Mass balance and excretion In vivo metabolism-radiolabeled and non-radiolabeled studies In vitro metabolic stability in S9, microsomes and hepatocytes a Intrinsic clearance studies a In vitro metabolic profiling and metabolite Characterization by LC-MS/MS a Protein binding and blood cell partitioning a Subcontracted to third party 18

Bioanalytical Services Small molecules and proteins LC-MS/MS a Method development/validation Custom analytical method development and validation UV-HPLC and spectrophotometry Rapid turnaround, data conform to clientʼs database requirements Analytical trouble-shooting and consultancy Licensed for a wide range of radionuclides a Subcontracted to third party 19

Safety Pharmacology Services Core studies Neuropharmacological Profile in Mice or Rats herg Channel (subcontracted) Ancillary studies (included but not limited to): Diuretic Assay in Rats Isolated Guinea Pig Ileum GI Propulsion Assay in Mice and Rats Barbiturate Sleep Time in Mice or Rats Action Potential in Canine or Rabbit Purkinje Fiber herg (subcontracted) Cardiovascular (QT/QTc) Assay in Dogs (in vivo) 20

Discovery Pharmacology Services Anti-inflammatory/analgesia Cardiovascular Diabetes/obesity Other Diuretic assay in rats Renal function in dogs In vivo hair growth model in mice Ulcerogenic study in rats 21

Immunology Services Autoimmune/inflammatory disease models Tumor studies Anti-infective models ELISA and RIA assays Antigenicity/hypersensitivity studies Immunomodulation studies Blood compatibility assays Immunotoxicology 22

Animal Models We routinely perform all of the previously mentioned studies in all conventional species including: Rats, cotton rats, mice Guinea pigs, hamsters Rabbits Dogs Minipigs Nonhuman primates (cynamolgus) 23

Dose Administration Routes Parenteral Intraarterial Injection Intraarticular injection Intracystic instillation Intradermal injection Intraglandular injection Intramuscular injection Intraperitoneal injection Intravenous injection Intravitreal injection Enteral Oral Intraesophageal Intrarectal Topical Epicutaneous Intranasal Ocular Other Intravaginal 24